The consequences of some of these problems are exemplified in the results of the peer review studies of sarcomas which have been undertaken (Baker et al., 1978; Presant et al., 1986; Newton et al., 1988; Shiraki et al., 1989; Alvegard & Berg, 1989) . In these series histological sub-type of sarcoma was frequently changed on review and significant proportions of tumours were considered ineligible as sarcomas.
Bone and soft tissue sarcomas are rare tumours accounting for less than 1% of all malignancies (Muir et al., 1987) . Accurate diagnosis of sub-type of sarcoma is important in studies of incidence and aetiology, and also in terms of clinical management of patients. Diagnosis, however, is often extremely difficult and made more so because the rarity of certain sub-types of sarcoma results in relatively few cases being seen by any individual pathologist. In addition, criteria for diagnosis of sub-type have changed markedly over the last few decades and some are relatively newly defined. Even with the advent of immunohistochemical techniques, a certain proportion of cases remain unclassifiable, and there may be difficulties in distinguishing sub-types of similar appearance.
The consequences of some of these problems are exemplified in the results of the peer review studies of sarcomas which have been undertaken (Baker et al., 1978; Presant et al., 1986; Newton et al., 1988; Shiraki et al., 1989; Alvegard & Berg, 1989) . In these series histological sub-type of sarcoma was frequently changed on review and significant proportions of tumours were considered ineligible as sarcomas.
The study undertaken here was an attempt to define accurately the incidence of sub-types of sarcomas in a population-based series from North West England. This paper describes the results of case review by a panel of five pathologists.
Methods
Listings were obtained of all cases registered as sarcomas with the North Western Regional Cancer Registry for the years 1982, 1983 and 1984. In addition all cancer registrations for these years were scrutinised individually to identify cases not officially registered as sarcomas but where sarcoma was mentioned as a differential diagnosis in the pathology report or was recorded as part of death certification.
Cases included in the study were those malignant soft tissue sarcomas given in the modified WHO scheme described by Enzinger and Weiss (1988) The statistical software package SPSS/PC + was used to construct frequency tables and cross-tabulations (Norusis, 1989) . The original cancer registry diagnoses were compared between the group of cases that were reviewed and the group that were not using the chi-square test. The percentage of reviewed cases with an original diagnosis of sarcoma that had a final diagnosis of sarcoma was calculated as was the percentage of reviewed cases with an original diagnosis of a specific type of sarcoma that had the same final diagnosis.
For certain types of sarcoma a two by two table was constructed of original diagnosis against final diagnosis, both partitioned according to whether or not the diagnosis was the particular type of sarcoma under consideration, and Cohen's kappa (Fleiss, 1981) was used to measure the degree of agreement between the cancer registry and panel. Cohen's kappa takes a value of zero for chance agreement and a value of one for perfect agreement. For reviewed cases with a final diagnosis of sarcoma, the percentages which were identified as neoplastic, as malignant and as sarcoma prior to panel review were calculated separately for each pathologist. Similarly for all reviewed cases with a final diagnosis of a specific type of sarcoma and for certain sub-types of sarcoma the percentage agreement with the final diagnosis was calculated for each pathologist.
Results
The total number of cancer registrations scrutinised for the study was 59,784 (19,550 for 1982, 19,980 for 1983 and 20,254 for 1984) . Of these 450 cases were registered as sarcomas. A further five cases were selected for review because of possible uncertainty in diagnosis or in grade of malignancy (two giant cell tumours of bone, and one each of haemangioendothelioma, haemangiopericytoma and atypical fibroxanthoma). In addition, 13 cases not registered as sarcomas but where the possibility of sarcoma was mentioned on the registration form, were included for review (eight carcinomas, one seminoma, one lymphoma, one neurofibromatosis and two malignant tumours NOS). Hence a total of 468 cases was entered in the study. Bone tumours accounted for 92 cases and soft tissue tumours for the remaining 376. The original recorded histology for all cases is shown in Table I availability of some material, six (1.4%) were seen by only four pathologists, six (1.4%) by three and the remaining two (0.5%) by two pathologists. Final diagnoses were arrived at by the panel for 421 of the 429 reviewed cases. The broad histological categories of the final diagnoses were as follows: sarcoma, specified histology 279; sarcoma NOS 36; connective tissue tumour of borderline malignancy 12; benign connective tissue tumour 13; carcinoma 29; other specified malignant tumour 20; malignant tumour NOS 23; non-neoplastic condition nine; and non-diagnosable material eight. Of the five cases included because of possible uncertainty in diagnosis the original diagnoses of giant cell tumour of bone and atypical fibroxanthoma were confirmed, the case of haemangiopericytoma could only be defined as a borderline soft tissue tumour and no tumour tissue was obtained for the case of haemangioendothelioma. Hence none of these five cases contributed to the final total of sarcomas. For the 13 cases not registered as sarcomas but included in the study because of mention of sarcoma on the registration form, only two had a final diagnosis of sarcoma, one previously diagnosed as malignant spindle cell tumour and another as transitional cell carcinoma.
Of the 421 cases with agreed final diagnoses, 315 were confirmed as sarcomas by the panel, 58 of bone and 257 of soft tissue. specific subtype of sarcoma had previously been specified the panel agreed with the sub-type in only 53% of cases, although they were able to specify a sub-type in 56% of previously nonspecified cases.
These results are, in general, consistent with those of similar studies. Presant et al. (1986) reported the review of specimens from 216 consecutive patients with bone or soft tissue sarcomas entered into trials conducted by the Southeastern Cancer Study Group (SEG). Most cases were reviewed by one or two pathologists in addition to the original reviewer, and there was agreement between primary reviewer and panel in 66% cases. In 27% there was disagreement over sub-type and 6% cases were considered not to be sarcomas. Reports of a similar panel review of 130 cases of disseminated soft tissue sarcoma by the Southwest Oncology Group (Baker et al., 1978) showed total agreement on subtype in 62% cases, disagreement in 32% and a non-sarcoma diagnosis in 7%. Review of 240 patients aged 15-70 years with localised high grade soft tissue sarcomas by the Scandinavian Sarcoma Group (Alvegard et al., 1989 ) also resulted in change of sub-type in 25% cases and in 5% of cases being rejected as non-sarcomas.
Change in diagnosis from sarcoma to other tumours in the three studies described above was consistent at 5-7% cases. One of the striking results of this study was the much larger proportion of cases (22%) where such a change was made. In 15% the change was to other types of malignant tumour or malignant tumour NOS, in 3% to benign tumours, in 2% to borderline tumours and in 2% to non-neoplastic conditions (the remaining 2% were unclassified). The reason for this high level of reclassification probably lies in the fact that this was a population-based series whereas previous studies were based upon cases referred for trials of adjuvant therapy. Hence many of the cases in this series would not have been referred to specialist centres for treatment because, for example, they were very elderly, had advanced disease at diagnosis, or were only diagnosed at post-mortem examination. In addition because of the wide geographical spread of the cases, the original specimens had been reported by a large number of different pathologists, some of whom would see very few cases of sarcoma each year.
Because of small numbers, statistical measures of agree- Diagnosis of liposarcoma was very variable, with only 17 of 35 confirmed. The majority of cases of rhabdomyosarcoma (RMS) were also reclassified (16 out of 25) on review. This is in contrast with the findings of Newton et al. (1988) who reported 94% agreement between the review committee and institutional pathologists in the diagnosis of RMS, although much less agreement on sub-type. This discrepancy is again probably related to the type of patient entered into the study.
Perhaps the most striking reclassification was of fibrosarcoma with only two out of 28 cases confirmed. Five were reclassified as MFH, four as leiomyosarcoma, five as sarcoma NOS and the rest were spread over a variety of different types. Fibrosarcoma was the most common sarcoma diagnosis made 30 years ago but has perhaps been the most affected by changing diagnostic criteria until at the present time the diagnosis is rarely made.
The study demonstrated a high degree of agreement on the diagnosis of sarcoma between individual pathologists on the panel, although the diagnosis of sub-type was much less consistent. Because, however, Type A and Type B agreements were accepted for sub-type comparisons, the bias was in favour of those pathologists who submitted more than two differential diagnoses, rather than those whose diagnoses were more precise. Differences between pathologists may reflect their experience in terms of numbers of sarcomas reviewed prior to taking part in the study and also their differing expertise in relation to bone or soft tissue tumours.
While the degree of disagreement between original diagnosis and final panel diagnosis, and between individual pathologists and the final panel diagnosis is disturbing, it should perhaps be noted that while being a consistent finding for histopathological studies of sarcomas, such reclassification is much less common for most other types of malignant disease (Whitehead et al., 1984) .
Variation between the opinions of the original pathologist and the panel members is inevitable. In some cases the panel may have received unrepresentative samples of the tumour for review, especially where there was histological variability between areas of tumour, and in other cases inadequate provision of different samples of the same tumour could have resulted in the mis-diagnosis of grade of malignancy. Nevertheless it is surprising that, in spite of seeing relatively large numbers of sarcomas over and above normal workload, such variation in diagnosis between panel members continued to occur and although no formal assessment of converging agreement with time was made, the general impression was that this did not take place. This impression is consistent with that of Presant et al. (1986) who found no improvement in frequency of agreement in the course of the SEG study, in spite of educational workshops. The only conclusion which can be drawn from this is that second opinion is of vital importance in cases of presumed sarcomas, particularly for those cases e.g. MFH where concordance in diagnosis appears to be low. Review is essential so that correct treatment is selected for those patients who are almost certain to have sarcomas and so that inappropriate therapy is not given to cases who do not have sarcomas, or who have only benign or boderline or non-neoplastic conditions.
